AR and benign prostatic hyperplasia: Circulating androgen and the AR signaling, both epithelial and stromal AR, play critical roles in the pathogenesis of BPH, and that partially blockade of AR signaling, such as 5-α reductase inhibitors, decreases the BPH volume [15, 16].